Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRG | P62508 | 3/20 | 0.46 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | MC4R | P32245 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3617101 | 0.94 | ESRRG (0.42) | ESRRGACKR3NPC1RAB9AALDH1A1 | |
| SCHEMBL3170020 | 0.89 | ESRRG (0.49) | ESRRGACKR3NPC1RAB9AALDH1A1 | |
| SCHEMBL3179535 | 0.74 | POLB (0.53) | RAB9AALDH1A1KDM4EHPGDHTT | |
| SCHEMBL8171265 | 0.74 | POLB (0.53) | RAB9AALDH1A1KDM4EHPGDHTT | |
| SCHEMBL3170205 | 0.70 | RAB9A (0.50) | ESRRGNPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL5844175 | 0.70 | HPGD (0.66) | ESRRGACKR3RAB9AALDH1A1KDM4E | |
| SCHEMBL3164350 | 0.68 | KMT2A (0.49) | NPC1RAB9AALDH1A1HTTKMT2A | |
| SCHEMBL3607180 | 0.68 | ALDH1A1 (0.39) | NPC1RAB9AALDH1A1HPGDHTT | |
| SCHEMBL22063680 | 0.67 | HSD17B2 (0.40) | HSD17B2 | |
| SCHEMBL7162476 | 0.66 | HPGD (0.55) | NPC1RAB9AALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304438-B2 | Heteroarylacrylamides and their use as pharmaceuticals | SANOFI (FR) | 2012-11-06 | — | — | US | disclosed |
| US-8188291-B2 | Heteroaryl-substituted carboxamides and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| US-20100016272-A1 | HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2010-01-21 | — | — | US | disclosed |
| US-20100016337-A1 | HETEROARYL-SUBSTITUTED CARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2010-01-21 | — | — | US | disclosed |
| EP-2099753-A2 | HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2009-09-16 | — | — | EP | disclosed |
| EP-2097382-A1 | HETEROARYL-SUBSTITUTED CARBOXAMIDES AND USE THEREOF FOR THE STIMULATION OF THE EXPRESSION OF NO SYNTHASE | Sanofi-Aventis (FR) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008077507-A1 | HETEROARYL-SUBSTITUTED CARBOXAMIDES AND USE THEREOF FOR THE STIMULATION OF THE EXPRESSION OF NO SYNTHASE | SANOFI-AVENTIS (FR) | 2008-07-03 | — | — | WO | disclosed |
| EP-1939181-A1 | Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase | sanofi-aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
| EP-1939180-A1 | Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase | sanofi-aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
| WO-2008074413-A2 | HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS FOR THE STIMULATION OF THE EXPRESSION OF ENDOTHELIAL NO SYNTHASE | SANOFI-AVENTIS (FR) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016272-A1 | HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | NOS3, PTGIS, NOS1 | ESRRG 166/4885ACKR3 1450/4885NPC1 4260/4885 |
| US-20100016337-A1 | HETEROARYL-SUBSTITUTED CARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | TBXAS1, PTGIS, NOS2 | ESRRG 402/4885ACKR3 2552/4885NPC1 2911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.